Corticosteroid-Free Remission Through 3 Years of Upadacitinib Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 Long-Term Extension Study U-ACTIVATE.

Upadacitinib was superior to placebo across clinical, endoscopic, and histologic endpoints; was effective in achieving corticosteroid-sparing treatment; and was well tolerated in the U-ACHIEVE maintenance study. In the U-ACTIVATE LTE trial, a phase 3, multicenter, randomized, double-blind, placebo-controlled clinical program, corticosteroid-free and symptomatic remission was achieved with upadacitinib maintenance treatment and was maintained in more than 80% of patients through 48 weeks. Patients from the LTE study were further assessed up to 96 weeks. Most of these patients achieved and maintained corticosteroid-free CR, suggesting that upadacitinib continues to have a persistent benefit, is an excellent long-term treatment option for moderately to severely active UC, and can spare patients from corticosteroid use. [ABSTRACT FROM AUTHOR]